Related Experiment Video

Updated: Jul 18, 2026

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

Pelizaeus-Merzbacher disease: Genetic and cellular pathogenesis

J Y Garbern1

  • 1Department of Neurology and Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, 421 E Canfield Room 3217, Detroit, MI 48201, USA. jgarbern@med.wayne.edu

Cellular and Molecular Life Sciences : CMLS
|November 23, 2006
PubMed

Insights

Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia type 2 (SPG2) result from mutations in the myelin proteolipid protein (PLP) gene. Understanding PLP1 mutation effects on myelinating cells is key for disease management and therapy development.

Area of Science:

  • Neuroscience
  • Genetics
  • Cell Biology

Background:

  • Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia type 2 (SPG2) are X-linked disorders caused by mutations in the gene for proteolipid protein 1 (PLP1).
  • PLP is the primary protein component of myelin in the central nervous system (CNS).
  • Mutations in PLP1 impact the function of myelinating glia and nervous system integrity.

Purpose of the Study:

  • To analyze the spectrum of mutations affecting PLP and their consequences.
  • To elucidate the roles of myelinating glia in maintaining nervous system integrity.
  • To understand the broad disease spectrum of PMD and SPG2.

Main Methods:

  • Analysis of mutations in the PLP1 gene.
  • Investigation of cell-autonomous and non-cell-autonomous effects of PLP1 mutations.
  • Correlation of mutation types with disease presentation.

Main Results:

  • PLP1 mutations lead to a wide range of neurological deficits, defining the spectrum of PMD and SPG2.
  • These mutations affect both intrinsic cellular functions and intercellular interactions within myelinating cells.
  • The findings highlight critical roles for myelinating glia beyond simple myelination.

Conclusions:

  • The broad spectrum of PMD and SPG2 is explained by diverse PLP1 mutations and their multifaceted cellular effects.
  • Understanding these genetic and cellular impacts is crucial for accurate patient counseling and disease pathogenesis.
  • This knowledge is foundational for developing targeted therapies for PMD and SPG2.

More Related Videos

Detection of Nuclear Blebbing and DNA Leakage in Mammalian Cells by Immunofluorescence06:23

Detection of Nuclear Blebbing and DNA Leakage in Mammalian Cells by Immunofluorescence

Published on: January 17, 2025

Modeling Mitochondrial Disease Using Brain Organoids: A Focus on Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes08:56

Modeling Mitochondrial Disease Using Brain Organoids: A Focus on Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes

Published on: October 10, 2025

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...